Attila Imre

Dr. Attila Imre

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in British Journal of Pharmacology
Verified
Journal Article
Open access
Attila ImreAttila Imre
Attila Imre
BBBalázs Balogh
Balázs Balogh
IMIstván Mándity
István Mándity
Background and Purpose: Cell‐penetrating peptides (CPPs) are short amino acid sequences that can penetrate cell membranes and deliver molecules into cells. Several models have been developed for their discovery, yet these models often face challenges in accurately predicting membrane penetration due to the complex nature of peptide–cell interactions. Hence, there is a need for innovative approaches that can enhance predictive performance.Experimental Approach: In this study, we present the application GraphCPP, a novel graph neural network (GNN) for the prediction of membrane penetration capability of peptides.Key Results: A new comprehensive dataset—dubbed CPP1708—was constructed resulting in the largest reliable database of CPPs to date. Comparative analyses with previous methods, such as MLCPP2, C2Pred, CellPPD and CellPPD‐Mod, demonstrated the superior predictive performance of our model. Upon testing against other published methods, GraphCPP performs exceptionally, achieving 0.5787 Matthews correlation coefficient and 0.8459 area under the curve (AUC) values on one dataset. This means a 92.8% and 23.3% improvement in Matthews correlation coefficient and AUC measures respectively compared with the next best model. The capability of the model to effectively learn peptide representations was demonstrated through t‐distributed stochastic neighbour embedding plots. Additionally, the uncertainty analysis revealed that GraphCPP maintains high confidence in predictions for peptides shorter than 40 amino acids. The source code is available at https://github.com/attilaimre99/GraphCPP.Conclusion and Implications: These findings indicate the potential of GNN‐based models to improve CPP penetration prediction and it may contribute towards the development of more efficient drug delivery systems.

18 August 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
Attila ImreAttila Imre
Attila Imre
BNBalazs Nagy
Balazs Nagy
RHRok Hren
Rok Hren
Aims: Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences. The secondary objective is to explore value‐based pricing thresholds in line with Dutch health economic guidelines.Methods: Using the ErasmusMC/iMTA MS microsimulation model, we compared IMMUTOL gene therapy against various high‐efficacy and escalation‐based disease‐modifying therapy sequences. Analyses considered a lifetime horizon, societal and healthcare perspectives, and uncertainty through probabilistic sensitivity analysis. The IMMUTOL gene therapy scenarios varied in efficacy parameters (relapse and disability reduction) and adverse event profiles. Cost assumptions incorporated projected market dynamics, including future price reductions due to generics and biosimilars.Results: IMMUTOL gene therapy demonstrated dominance (higher quality‐adjusted life years, lower costs) at price points ≤€200 000 and remained cost‐effective at €500 000 under realistic clinical scenarios (incremental cost‐effectiveness ratio €26 570–€40 615/quality‐adjusted life year). Its cost‐effectiveness threshold depended on sustained reductions in relapse rates and disability progression (incidence rate ratio ≤0.2, relative risk ≤0.1). Indirect societal costs improved gene therapy's economic attractiveness.Conclusions: IMMUTOL gene therapy shows promising cost‐effectiveness at a value‐based price up to approximately €500 000, contingent on achieving curative clinical efficacy. These findings inform strategic development and pricing considerations for emerging gene therapies in MS.

22 July 2025 in Psychiatry Research
Verified
Journal Article
Open access
ZKZoltán Kaló
Zoltán Kaló
Attila ImreAttila Imre
Attila Imre
MTManna Tatár
Manna Tatár
BNBalazs Nagy
Balazs Nagy
Digital technologies, including artificial intelligence, hold great promise for transforming mental health care by enhancing diagnosis, personalizing treatments, and improving patient support. However, many innovations fail to reach clinical practice due to challenges in development and implementation. In this paper we address the implementation issue, whereby we introduce Early-stage Health Technology Assessment (eHTA) as a systematic approach to guide the development of digital technologies in mental health care. eHTA involves evaluating a technology's potential clinical benefits, economic value, and feasibility at an early stage. We present a five-step framework to assist developers of these inventions: (1) assessing the degree of innovation by determining how the new technology differs from existing solutions; (2) defining the target product profile by outlining its intended use, target population, and key features; (3) selecting an appropriate payment model by identifying who will pay for the technology and understanding their expectations; (4) translating clinical benefits into economically meaningful outcomes important to payers, such as improved clinical outcomes or cost savings; and (5) determining a pricing strategy that reflects the technology's value while remaining acceptable to payers and accessible to patients. By following these steps, innovators can align their technologies with clinical needs, generate necessary evidence, and create strategies for successful integration into mental health services. Incorporating early HTA in the development process is crucial for maximizing both the clinical impact and the successful adoption of digital technologies in mental health care.

27 March 2026 in Health Economics Review
Verified
Journal Article
Open access
PDF file
Attila ImreAttila Imre
Attila Imre
ÁMÁgota Mészáros
Ágota Mészáros
BNBertalan Németh
Bertalan Németh
BNBalázs Nagy
Balázs Nagy
JJJudit Józwiak-Hagymásy
Judit Józwiak-Hagymásy
BBBalázs Babarczy
Balázs Babarczy
Background: Existing studies on the economic impact of schizophrenia are fragmented and vary in methodology, hindering an ample understanding of the total economic burden. Aims: To quantify the global economic burden of schizophrenia by synthesizing findings from systematic reviews and meta-analyses, and to assess variations by cost category, world region and income level. Method: We conducted a protocol-driven umbrella review registered on PROSPERO (CRD42024504092). A systematic search of MEDLINE, EMBASE, Cochrane Library, and APA PsycINFO identified reviews reporting annual per-patient monetary cost estimates for schizophrenia. Monetary values were adjusted for inflation and converted to 2024 US dollars. Results: Twenty-six systematic reviews involving 152 primary studies were included. The median annual per-patient total cost of schizophrenia across included primary studies was $33,236 (mean $47,872), with direct costs accounting for $23,126 (medical: $19,543; ancillary: $1,152) and indirect costs for $21,333. Costs were varied by income level: in high-income countries, the median total cost was $34,175, compared to $3,345 in upper-middle-income and $3,452 in lower-middle-income countries. Regional disparities were substantial, with Europe & Central Asia reporting the highest median costs among high-income settings. Data from low- and middle-income regions were limited or absent. Methodological heterogeneity, lack of standardization in cost reporting, and underrepresentation of low-resource settings limit generalizability. Conclusions: The included cost-of-illness estimates indicate that schizophrenia is associated with substantial annual per-patient costs, with hospitalization, long-term care, and productivity losses frequently among the largest reported components. However, the evidence base is heavily weighted toward high-income countries, and limited data from lower-resource settings constrain cross-country comparability. Future research should adopt standardized costing frameworks and expand data collection in underrepresented regions to improve the consistency, transparency, and geographic coverage of economic burden estimates.

6 August 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
ZKZoltán Kaló
Zoltán Kaló
Attila ImreAttila Imre
Attila Imre
GVGábor Varga
Gábor Varga
SKSándor Kovács
Sándor Kovács
GTGyörgy Tímár
György Tímár
BNBalazs Nagy
Balazs Nagy
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations. Limited attention to building the health economic story during early development phases may ultimately result in suboptimal return on investment. Early‐phase health technology assessment (eHTA) provides a structured approach to value maximization. Selection of the payment model helps to understand what value propositions are taken into account, in general, by the target payers of the new medicine. Fair judgement on the degree of innovation at the expected launch date is essential to choose the relevant propositions from the general list of value drivers. Development of the conceptual value framework translates target product profile into policy‐relevant value propositions, such as health gain, expected cost savings through avoided medical events and delayed disease progression, value in use or health system benefits. Implementation of the health economics and outcomes research strategy helps to justify premium price based on added value and facilitate the appropriate order of target indications with the most return on investment. Effective integration of eHTA into the research and development process enables innovators to shorten time to reimbursement and increases the probability of clinical and commercial success for investigational medicinal products.

1 October 2025 in Analytica Chimica Acta
Verified
Journal Article
Open access
Attila ImreAttila Imre
Attila Imre
GDGergely Dombi
Gergely Dombi
MDMáté Dobó
Máté Dobó
Ali MhammadAli Mhammad
Ali Mhammad
EFElek Ferencz
Elek Ferencz
GTGergő Tóth
Gergő Tóth
Enantioseparation in HPLC is a considerable challenge in analytical chemistry, frequently requiring numerous trials with varying experimental conditions to achieve baseline separations. To address this issue, we propose a solution that utilizes consensus modelling based on partial least squares (PLS) regression method together with neural network (NN) algorithms and a graph neural network (GNN) method to predict the retention times of compounds on Lux Cellulose-1 chiral stationary phase under various polar organic mode mobile phases. A homogeneous dataset was collected for the developed machine learning methods, consisting of 535 unique molecules and 1,414 retention time measurements under four polar organic mode conditions (acidic and basic methanol, acidic and basic acetonitrile). The PLS + NN consensus model showed outstanding results in condition-specific predictions, achieving R2 values over 0.70 and RMSE values below 0.40 in most cases. Conversely, the GNN model excelled in combined predictions under all conditions, achieving a R2 of 0.58 and RMSECV of 0.49 during cross-validation, as well as a R2 of 0.85 and RMSETest of 0.25 on the test set. Our research presents a novel approach for predicting chiral separations, offering an easy-to-use, open-access web tool to the scientific community. The robust GNN model was used to create a web server (https://chiralscreen.com) that enables the prediction of retention times, separation capabilities, and elution orders for various compounds. Furthermore, the software helps determine optimal initial chromatographic conditions for separations.